Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group

Winfried Amoaku,1 Konstantinos Balaskas,2,3 Tomas Cudrnak,4 Louise Downey,5 Markus Groppe,6 Sajjad Mahmood,7 Hemal Mehta,8 Quresh Mohamed,9 Bushra Mushtaq,10 Philip Severn,11 Athanasios Vardarinos,12 Yit Yang,13 Saad Younis14 1Academic Ophthalmology, Division of Clinical Neuroscience, University of...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Amoaku W, Balaskas K, Cudrnak T, Downey L, Groppe M, Mahmood S, Mehta H, Mohamed Q, Mushtaq B, Severn P, Vardarinos A, Yang Y, Younis S
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2018
Materias:
ranibizumab
age-related macular degeneration
nAMD
treat and extend
anti-VEGF treatment.
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/54ecb5ae5ee04cb69e3504e3f24862e9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:54ecb5ae5ee04cb69e3504e3f24862e9
record_format dspace
spelling oai:doaj.org-article:54ecb5ae5ee04cb69e3504e3f24862e92021-12-02T00:52:47ZInitiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group1177-5483https://doaj.org/article/54ecb5ae5ee04cb69e3504e3f24862e92018-09-01T00:00:00Zhttps://www.dovepress.com/initiation-and-maintenance-of-a-treat-and-extend-regimen-for-ranibizum-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Winfried Amoaku,1 Konstantinos Balaskas,2,3 Tomas Cudrnak,4 Louise Downey,5 Markus Groppe,6 Sajjad Mahmood,7 Hemal Mehta,8 Quresh Mohamed,9 Bushra Mushtaq,10 Philip Severn,11 Athanasios Vardarinos,12 Yit Yang,13 Saad Younis14 1Academic Ophthalmology, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK; 2NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and University College of London Institute of Ophthalmology, London, UK; 3University of Manchester, Manchester, UK; 4Royal Eye Infirmary, University Hospitals Plymouth NHS Trust, Plymouth, UK; 5Hull and East Yorkshire Eye Hospital, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK; 6Ophthalmology, Stoke Mandeville, Buckinghamshire Healthcare NHS Trust, Aylesbury, UK; 7Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; 8Royal Free London NHS Foundation Trust, London, UK; 9Gloucestershire Eye Unit, Cheltenham General Hospital, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK; 10Birmingham and Midland Eye Centre, Sandwell and West Birmingham NHS Trust, Birmingham, UK; 11South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK; 12Eye Treatment Centre, West Suffolk Hospital, West Suffolk NHS Foundation Trust, Bury St Edmunds, UK; 13Wolverhampton Eye Infirmary, The Royal Wolverhampton NHS Trust, Wolverhampton, UK; 14Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London, UK Abstract: The treatment of neovascular (wet) age-related macular degeneration (AMD) with ranibizumab is now very well established in terms of efficacy and safety. Recent clinical trials and real-world studies have demonstrated the advantages of a Treat-and-Extend (T&E) regimen, and many hospital departments are now in the process of adopting this new regimen in favor of the pro re nata regimen for initiating and continuing ranibizumab therapy for patients with wet AMD. The comprehensive spectrum of issues related to implementation of the regimen is covered qualitatively in ten didactic topics provided by a group of clinicians with direct experience of this regimen in their department. The topics include definition, new and previously treated eyes, management of high-frequency injections, maximum extensions, discontinuing T&E, bilateral cases, clerical, audit, and patient counseling. This article aims to provide a useful resource for the implementation of the T&E regimen. A quantitative summary of the visual outcomes in key publications is also provided in this article. This article should be a valuable resource for staff training. Keywords: ranibizumab, age-related macular degeneration, nAMD, Treat and Extend, anti-VEGF treatmentAmoaku WBalaskas KCudrnak TDowney LGroppe MMahmood SMehta HMohamed QMushtaq BSevern PVardarinos AYang YYounis SDove Medical Pressarticleranibizumabage-related macular degenerationnAMDtreat and extendanti-VEGF treatment.OphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 1731-1740 (2018)
institution DOAJ
collection DOAJ
language EN
topic ranibizumab
age-related macular degeneration
nAMD
treat and extend
anti-VEGF treatment.
Ophthalmology
RE1-994
spellingShingle ranibizumab
age-related macular degeneration
nAMD
treat and extend
anti-VEGF treatment.
Ophthalmology
RE1-994
Amoaku W
Balaskas K
Cudrnak T
Downey L
Groppe M
Mahmood S
Mehta H
Mohamed Q
Mushtaq B
Severn P
Vardarinos A
Yang Y
Younis S
Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
description Winfried Amoaku,1 Konstantinos Balaskas,2,3 Tomas Cudrnak,4 Louise Downey,5 Markus Groppe,6 Sajjad Mahmood,7 Hemal Mehta,8 Quresh Mohamed,9 Bushra Mushtaq,10 Philip Severn,11 Athanasios Vardarinos,12 Yit Yang,13 Saad Younis14 1Academic Ophthalmology, Division of Clinical Neuroscience, University of Nottingham, Nottingham, UK; 2NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and University College of London Institute of Ophthalmology, London, UK; 3University of Manchester, Manchester, UK; 4Royal Eye Infirmary, University Hospitals Plymouth NHS Trust, Plymouth, UK; 5Hull and East Yorkshire Eye Hospital, Hull and East Yorkshire Hospitals NHS Trust, Hull, UK; 6Ophthalmology, Stoke Mandeville, Buckinghamshire Healthcare NHS Trust, Aylesbury, UK; 7Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK; 8Royal Free London NHS Foundation Trust, London, UK; 9Gloucestershire Eye Unit, Cheltenham General Hospital, Gloucestershire Hospitals NHS Foundation Trust, Gloucester, UK; 10Birmingham and Midland Eye Centre, Sandwell and West Birmingham NHS Trust, Birmingham, UK; 11South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK; 12Eye Treatment Centre, West Suffolk Hospital, West Suffolk NHS Foundation Trust, Bury St Edmunds, UK; 13Wolverhampton Eye Infirmary, The Royal Wolverhampton NHS Trust, Wolverhampton, UK; 14Ophthalmology, Western Eye Hospital, Imperial College Healthcare NHS Trust, London, UK Abstract: The treatment of neovascular (wet) age-related macular degeneration (AMD) with ranibizumab is now very well established in terms of efficacy and safety. Recent clinical trials and real-world studies have demonstrated the advantages of a Treat-and-Extend (T&E) regimen, and many hospital departments are now in the process of adopting this new regimen in favor of the pro re nata regimen for initiating and continuing ranibizumab therapy for patients with wet AMD. The comprehensive spectrum of issues related to implementation of the regimen is covered qualitatively in ten didactic topics provided by a group of clinicians with direct experience of this regimen in their department. The topics include definition, new and previously treated eyes, management of high-frequency injections, maximum extensions, discontinuing T&E, bilateral cases, clerical, audit, and patient counseling. This article aims to provide a useful resource for the implementation of the T&E regimen. A quantitative summary of the visual outcomes in key publications is also provided in this article. This article should be a valuable resource for staff training. Keywords: ranibizumab, age-related macular degeneration, nAMD, Treat and Extend, anti-VEGF treatment
format article
author Amoaku W
Balaskas K
Cudrnak T
Downey L
Groppe M
Mahmood S
Mehta H
Mohamed Q
Mushtaq B
Severn P
Vardarinos A
Yang Y
Younis S
author_facet Amoaku W
Balaskas K
Cudrnak T
Downey L
Groppe M
Mahmood S
Mehta H
Mohamed Q
Mushtaq B
Severn P
Vardarinos A
Yang Y
Younis S
author_sort Amoaku W
title Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
title_short Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
title_full Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
title_fullStr Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
title_full_unstemmed Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group
title_sort initiation and maintenance of a treat-and-extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the uk retinal outcomes group
publisher Dove Medical Press
publishDate 2018
url https://doaj.org/article/54ecb5ae5ee04cb69e3504e3f24862e9
work_keys_str_mv AT amoakuw initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup
AT balaskask initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup
AT cudrnakt initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup
AT downeyl initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup
AT groppem initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup
AT mahmoods initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup
AT mehtah initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup
AT mohamedq initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup
AT mushtaqb initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup
AT severnp initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup
AT vardarinosa initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup
AT yangy initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup
AT youniss initiationandmaintenanceofatreatandextendregimenforranibizumabtherapyinwetagerelatedmaculardegenerationrecommendationsfromtheukretinaloutcomesgroup
_version_ 1718403438887305216

Ejemplares similares